Funding21 Oct 20264 min read

Coherence Neuro raises $45M to take its brain-cancer implant into a long-term trial

Founders Fund and the OpenAI Startup Fund co-led the round. The case rests on mouse recordings in a preprint and a probe that recorded for half an hour in each of three patients; whether its stimulation can slow a tumour has not been tested in a person.

ByThe BCI Briefing

Evidence class: Reported claim

The short version

Coherence Neuro raised $45M in a Series A co-led by Founders Fund and the OpenAI Startup Fund, OpenAI's venture fund. WIRED called it a seed round; the company raised a $10M seed in November 2025.
So far, chronic recordings in mice tracked glioma growth in a preprint, and in people a thin-film probe recorded for about half an hour in each of three patients during surgery.
The money is for a first chronic trial in glioblastoma. Whether stimulation from an implant slows a tumour has not been tested in a person.

Coherence Neuro announced the round on 21 October. Lux Capital and 8VC are among the new investors; Blackbird, Topology and Artesian, which backed the seed, put in more. Neuralink's head neurosurgeon, Matthew MacDougall, and one of its principal investigators, Rory Murphy, invested as angels. The company says the money will pay for its first chronic human trial in glioblastoma, an application for FDA Breakthrough Device designation and preclinical work in pancreatic cancer.

The money comes from the OpenAI Startup Fund, which WIRED describes as OpenAI's venture arm. OpenAI took a different route in January, when it put money directly into Merge Labs, the ultrasound BCI company co-founded by Sam Altman, and said it would work with it on foundation models. Ben Woodington, Coherence's chief executive, told WIRED that nothing in its contracts gives OpenAI access to brain or health data.

Two devices are involved. CIPHER is a flexible thin-film probe laid on the cortex during glioma surgery at the Royal Melbourne Hospital; the registered study plans ten patients, some recorded and some also stimulated, just before the tumour is removed, and measures safety, signal quality and how local field potentials change after stimulation. SOMA, the planned product, is an implant the size of a shirt button with up to 16 threads that would record and stimulate around a tumour, powered by a wearable behind the ear. The company calls its pictures of it concept images.

The science underneath is peer reviewed. In 2019 Michelle Monje's laboratory at Stanford showed that gliomas form synapses with neurons, and that blocking the signalling slowed tumour growth in mice. In 2023 a study of patients found that tumours more strongly connected to the surrounding brain went with shorter survival. Monje is an author of Coherence's preprint, in which chronic recordings in mice tracked tumour burden, gamma-band activity rose as gliomas grew, and models fitted to that activity predicted individual growth rates over five weeks, with and without temozolomide.

Why it matters

Between scans months apart, the course of a glioblastoma is largely unseen, and the company argues that an implant could follow it continuously. The distance from the evidence to that aim is long. The mouse result is the company's own preprint. In people, CIPHER has been used for minutes, in anaesthetised patients whose tumours were about to be removed, which can speak to safety and signal and not to whether tumour activity can be followed over months or changed by stimulation. Coherence's announcement points to tumour-treating fields, which the FDA approved for glioblastoma in 2011 and for locally advanced pancreatic cancer in February 2026. Those are applied through arrays on the head and record nothing. Coherence proposes stimulation from an implant, steered by what the implant records, and its chronic trial has not begun.

How solid is this

The amount, the round's name and the investors come from the company's announcement. WIRED reported the same amount and called it a seed round; the Briefing records a Series A, after the $10M seed of November 2025. The mouse findings are in a bioRxiv preprint, not yet peer reviewed, first posted in July and now in its fourth version (16 October). Human use: the ClinicalTrials.gov record (NCT07465796) and WIRED's report of three patients recorded for about 30 minutes each. No human data are published. The cancer-neuroscience findings it builds on are peer reviewed, in Nature in 2019 and 2023.

Company reported. Stated by the company itself in a release, blog post or presentation. Not independently verified and usually without full methods.

What to watch

01Registration of the chronic glioblastoma trial. Its endpoints will show whether it tests safety, signal or the tumour itself.
02Results from the ten-patient CIPHER study, including signal quality at the tumour margin and any change after stimulation.
03Peer review of the mouse preprint.

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Sources

01
Coherence Neuro: Inventing cancer therapy that learns (opens in a new tab)
Company reportedCoherence Neuro21 Oct 2026Checked against source 22 Oct 2026
Announces a $45M Series A co-led by Founders Fund and the OpenAI Startup Fund, with Lux Capital, 8VC, Timeless, Olive Capital and Ahren, and follow-on from Blackbird, Possible, Topology, Artesian, XEIA, Xtal and Divergent. Plans: a first chronic human trial in glioblastoma, an FDA Breakthrough Device application, and preclinical work in pancreatic cancer. Calls its device images concept images.
02
OpenAI invests in startup that uses brain implants to detect cancer (opens in a new tab)
Independent reportingWIRED (Emily Mullin)21 Oct 2026Checked against source 22 Oct 2026
Calls the $45M round a seed round. Reports that the implant recorded for about 30 minutes in three people during tumour surgery at the Royal Melbourne Hospital, that recording and stimulation are being tested in seven more, and that the company says OpenAI will have no access to its data.
03
Stroud JP et al. Neural signatures of glioma progression using implanted neural interfaces. bioRxiv 2026.07.01.735772 (version 4) (opens in a new tab)
PreprintbioRxiv7 Jul 2026Checked against source 22 Oct 2026
Not peer reviewed; first posted 7 July 2026, fourth version 16 October 2026. Coherence Neuro with Michelle Monje (Stanford). In mice with gliomas, chronic recordings tracked tumour burden measured by bioluminescence; gamma-band activity rose with progression in glioblastoma and DIPG models; models fitted to gamma-band trajectories predicted individual growth rates over five weeks.
04
Venkatesh HS et al. Electrical and synaptic integration of glioma into neural circuits. Nature 2019;573:539–545 (opens in a new tab)
Peer reviewedNature18 Sep 2019Checked against source 22 Oct 2026
Neuron-to-glioma synapses and activity-dependent currents promote glioma growth in mice; blocking that signalling slowed xenograft growth and extended survival; intraoperative ECoG showed increased excitability in glioma-infiltrated human cortex.
05
Krishna S et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature 2023;617:599–607 (opens in a new tab)
Peer reviewedNature3 May 2023Checked against source 22 Oct 2026
Intracranial recordings in awake patients showed language tasks activating tumour-infiltrated cortex; greater functional connectivity between tumour and brain went with shorter survival.
06
ClinicalTrials.gov NCT07465796: A first-in-human study of the CIPHER system during brain surgery for newly diagnosed glioma (opens in a new tab)
Clinical registryClinicalTrials.govChecked against source 5 Oct 2026
Sponsor Coherence Neuro Australia Pty Limited. Recruiting since 22 May 2026 in Melbourne; 10 participants planned.
07
Coherence Neuro: SOMA product page (opens in a new tab)
Company reportedCoherence NeuroChecked against source 22 Oct 2026
Describes SOMA, the planned glioblastoma system, as an implant the size of a shirt button with up to 16 ultrathin threads that stimulate and record, placed during an existing resection or biopsy and powered by an over-ear wearable. Investigational and not approved by any regulator.
08
FDA premarket approval P100034: NovoTTF-100A System, later Optune and Optune Gio (Novocure) (opens in a new tab)
Regulatory sourceUS Food and Drug Administration (openFDA PMA records)8 Apr 2011Checked against source 22 Oct 2026
Approved in April 2011 for recurrent glioblastoma and in October 2015, with temozolomide, for newly diagnosed glioblastoma. A low electric field tumour-treatment stimulator delivered through transducer arrays placed on the patient's head.
09
FDA premarket approval P250034: Optune Pax (Novocure) (opens in a new tab)
Regulatory sourceUS Food and Drug Administration (openFDA PMA records)11 Feb 2026Checked against source 22 Oct 2026
Approved for adults with locally advanced pancreatic cancer, together with gemcitabine and nab-paclitaxel.
10
Coherence Neuro raises $10M seed round for BCI that aids in cancer treatment (opens in a new tab)
Independent reportingMassDevice4 Nov 2025Checked against source 22 Oct 2026
A $10M seed led by Artesian and Topology Ventures, with pre-seed investors Blackbird and Possible Ventures, and XEIA Venture Partners, Jumpspace Ventures, Xtal, Divergent Capital, SmartGateVC, Spacewalk VC and angels. Based on the founders' LinkedIn posts.
11
Coherence Neuro raises $10m for cancer treatment technology (opens in a new tab)
Independent reportingCapital Brief4 Nov 2025Checked against source 22 Oct 2026
Names Artesian as the seed round's lead, with Topology Ventures among follow-on investors.